Topical vs Injectable Peptides (GHK-Cu)

Topical peptides act locally on the tissue they contact and depend on crossing the skin barrier, whereas injectable peptides bypass the barrier entirely to reach systemic circulation — so for GHK-Cu the right choice depends on whether the research target is the skin itself (favouring topical) or a systemic or deep-tissue effect (favouring injection).

This guide compares the two delivery routes using GHK-Cu as the worked example, covering absorption, bioavailability, and which route the literature supports for which endpoint. For the molecule's full pharmacology, see the GHK-Cu monograph.

Topical vs injectable peptides: the core difference

The defining variable is the stratum corneum, the skin's outer barrier, which excludes most molecules larger than ~500 Da (Bos & Meinardi, 2000, PMID: 11168751). Injection skips this barrier; topical application must overcome it.

Is GHK-Cu peptide better as injection or topical?

For skin and cosmetic endpoints, topical GHK-Cu is the more directly supported route because the skin is the target tissue and GHK-Cu's 340 Da molecular weight sits below the ~500 Da absorption cutoff, giving it relatively favourable penetration. For systemic or deep wound-repair research, subcutaneous injection achieves higher bioavailability but is not advantageous for surface skin outcomes.

How does absorption and bioavailability differ?

Topical bioavailability is intrinsically low — only a fraction of applied peptide crosses the stratum corneum, and the amount depends on molecular weight, the vehicle (liposomal and penetration-enhanced systems improve uptake), pH, and occlusion. Injectable delivery achieves near-complete bioavailability but introduces systemic exposure and, for research, requires reconstitution of lyophilized powder with bacteriostatic water and sterile technique. Smaller peptides such as GHK-Cu (340 Da) and SNAP-8 absorb better topically than large conjugated peptides.

What about oral GHK-Cu?

Oral delivery is a third route, but for peptides it is the weakest of the three. Ingested peptides are exposed to gastric acid and intestinal proteases that degrade most sequences before they can be absorbed intact, so oral GHK-Cu is not a meaningful route to deliver the active tripeptide to skin or systemic tissue. This is why GHK-Cu research concentrates on topical (for skin endpoints) and subcutaneous injection (for systemic and wound contexts) rather than ingestion. Note that "collagen peptides" sold as oral supplements are a different category entirely — they are hydrolysed dietary collagen, not the GHK-Cu signalling tripeptide.

Side-by-side: when to choose each route

The choice reduces to matching the route to the research target and accepting the trade-offs each carries:

• Choose topical when the endpoint is the skin or scalp itself — wrinkles, density, barrier, local antioxidant defence — and when a low-molecular-weight peptide like GHK-Cu can absorb. The trade-off is limited, vehicle-dependent bioavailability.
• Choose injectable when the research requires reaching deeper or systemic tissue. The trade-off is systemic exposure, the need for sterile reconstitution, and no advantage for surface skin outcomes.
• Avoid oral for peptide delivery, given proteolytic degradation.

Which route does the research support?

Match the route to the endpoint. Skin density, wrinkles, barrier function, and local antioxidant defence are best studied topically — that is where the human GHK-Cu evidence lies (Pickart & Margolina, 2018, PMID: 29987172). Systemic regeneration, deep tendon/GI repair, and wound models where reaching deeper tissue matters are studied via injection. See efficacy specifics in do topical peptides work and the cosmetic endpoint data in topical peptides for wrinkles.

Aevitas GHK-Cu — Research Grade

Whichever route your research design calls for, the input material is the same: Aevitas supplies GHK-Cu as a lyophilized powder at ≥98% HPLC purity with a third-party certificate of analysis in every batch.

[Read the GHK-Cu monograph →](/peptides/ghk-cu) · [Order GHK-Cu (50 mg) →](/product/ghk-cu-50mg) · View COA Library →

Frequently Asked Questions

Is GHK-Cu peptide injection or topical better? For skin endpoints, topical is the more directly supported route because the skin is the target and GHK-Cu absorbs relatively well at 340 Da. For systemic or deep-tissue research, injection achieves higher bioavailability.

Why is topical peptide absorption so limited? The stratum corneum excludes most molecules above ~500 Da, so only a fraction of applied peptide reaches the dermis. Molecular weight, vehicle, pH, and occlusion all influence how much is delivered.

Can you take GHK-Cu peptide oral or topical? Oral peptides are largely degraded by digestive proteases before absorption, which is why GHK-Cu research focuses on topical and injectable routes rather than ingestion.

Does injectable GHK-Cu work better for skin than topical? No — injection offers no clear advantage for surface skin outcomes because topical application already places the peptide at the target tissue.

---

Research Use Only · Not for human consumption · Not for veterinary use · None of the information on this page constitutes medical advice.

Related: GHK-Cu topical peptide guide · Topical peptides pillar · GHK-Cu monograph